Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2026)

Axsome Therapeutics' Change in Receivables history spans 5 years, with the latest figure at $26.6 million for Q1 2026.

  • On a quarterly basis, Change in Receivables rose 37.13% to $26.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $89.7 million, a 49.54% increase, with the full-year FY2025 number at $82.5 million, up 74.78% from a year prior.
  • Change in Receivables hit $26.6 million in Q1 2026 for Axsome Therapeutics, down from $28.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for AXSM hit a ceiling of $37.4 million in Q2 2025 and a floor of -$2.3 million in Q3 2025.
  • Historically, Change in Receivables has averaged $15.7 million across 5 years, with a median of $17.4 million in 2022.
  • The widest YoY moves for Change in Receivables: up 193.21% in 2025, down 161.75% in 2025.
  • Tracing AXSM's Change in Receivables over 5 years: stood at $17.4 million in 2022, then decreased by 5.7% to $16.4 million in 2023, then increased by 9.14% to $17.9 million in 2024, then surged by 56.14% to $28.0 million in 2025, then decreased by 4.86% to $26.6 million in 2026.
  • Business Quant data shows Change in Receivables for AXSM at $26.6 million in Q1 2026, $28.0 million in Q4 2025, and -$2.3 million in Q3 2025.